Kura Oncology, Inc. (KURA) is a publicly traded Healthcare sector company. As of November 3, 2026, KURA trades at $9.89 with a market cap of $912.74M and a P/E ratio of -3.18. KURA moved +0.00% today. Year to date, KURA is -5.22%; over the trailing twelve months it is -4.63%. Its 52-week range spans $5.41 to $13.90. Analyst consensus is strong buy with an average price target of $25.79. Rallies surfaces KURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kura Oncology-backed Caspian plans Phase 1 study of diabetes drug candidate KO-7246: Caspian Therapeutics plans a Phase 1 program for its diabetes candidate KO-7246, an oral menin inhibitor. Kura Oncology announced an Oct. 13, 2026, investor webcast with Caspian to outline its launch and review preclinical data previously presented at the EASD annual meeting.
| Metric | Value |
|---|---|
| Price | $9.89 |
| Market Cap | $912.74M |
| P/E Ratio | -3.18 |
| EPS | $-3.37 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.90 |
| 52-Week Low | $5.41 |
| Volume | 17.88K |
| Avg Volume | 0 |
| Revenue (TTM) | $77.22M |
| Net Income | $-296.77M |
| Gross Margin | 0.00% |
10 analysts cover KURA: 0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.79.